gefitinib
EGFR-Mutant NSCLC Patients See Similar Survival in Upfront Tagrisso Versus Sequential Treatment
Premium
A new analysis from the Phase II APPLE trial showed minimal differences in overall survival, though the newer generation TKI significantly reduced brain metastases.
The EGFR C797X mutation is the most common on-target resistance mechanism to EGFR TKIs, and drugmakers behind fourth-generation inhibitors are trying to tackle it.
Geneseeq Multi-Biomarker Approach Predicts EGFR-Mutated NSCLC Patients' Adjuvant Therapy Benefit
Premium
Geneseeq collaborated with researchers in China to generate three molecularly defined subgroups to guide adjuvant NSCLC treatment with either TKIs or chemotherapy.
Hansoh Pharma, EQRx Planning Regulatory Talks After Positive Phase III Aumolertinib Data in NSCLC
The firms' EGFR inhibitor improved progression-free survival versus gefitinib for advanced EGFR-mutated non-small cell lung cancer patients in the AENEAS trial.
Roche EGFR Mutation Test Approved by FDA as Companion Diagnostic for NSCLC
Roche's real-time PCR test detects defined mutations of the epidermal growth factor receptor gene in DNA from non-small cell lung cancer patients.